Startseite Evaluation of analytical performance of the Pathfast® cardiac troponin I
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Evaluation of analytical performance of the Pathfast® cardiac troponin I

  • Francesca Di Serio , Marco Caputo , Martina Zaninotto , Cosimo Ottomano und Mario Plebani
Veröffentlicht/Copyright: 20. Mai 2009
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

Background: Cardiac troponins are considered the cornestore for risk stratification and diagnosis of patients whit acute coronary syndrome (ACS). Following Clinical Laboratory Standards Institute (CLSI) guidelines, we assessed the analytical performances of the Pathfast® (Mitsubishi, Japan) cTnI method.

Methods: We evaluated different sample types. Control materials and lithium heparin plasma pools were used to determine: limit of blank (LoB), limit of detection (LoD), imprecision and linearity. The effects of potential endogenous interfering substances and the possibility of falsely increased cardiac troponin I (cTnI) concentrations attributable to the presence of heterophilic antibodies (HA), rheumatoid factor (RF) and human anti-mouse antibodies (HAMA) in high concentrations were evaluated. The 99th percentile limit of the cTnI value distribution was determined from 320 Caucasian reference individuals.

Results: No significant differences were found when cTnI concentrations of 40 lithium-heparin plasma samples were compared with the matched values of K2-EDTA plasma, whole blood and serum samples. The LoB and the LoD of the cTnI method were 0.0048 and 0.0066 μg/L, respectively. cTnI mean values from 0.66 to 6.0 μg/L showed a total CV% from 6.0 to 6.4. cTnI at a concentration of 0.02 μg/L was associated with a total CV of 9.6%. The method gave a linear response for cTnI concentrations within the measurement range. In six of 12 samples containing HA, a positive interference was demonstrated. The 99th percentile limit of the cTnI distribution in the reference population was 0.013 μg/L.

Conclusions: The data indicate that the cTnI Pathfast method may be suitable for helping clinicians in the management of patients with ACS.

Clin Chem Lab Med 2009;47:829–33.


Corresponding author: Francesca Di Serio, Department of Clinical Pathology I, University-Hospital of Bari, Piazza Giulio Cesare N. 11, 70124 Bari, Italy Phone: +39-080-5592629/124, Fax: +39-080-5592124,

Received: 2008-12-16
Accepted: 2009-3-31
Published Online: 2009-05-20
Published in Print: 2009-07-01

©2009 by Walter de Gruyter Berlin New York

Artikel in diesem Heft

  1. Editorials
  2. Change through continuity
  3. EFCC and Labs are Vital announce an Award for Outcomes Research in Laboratory Medicine
  4. Review
  5. The prevalence and risk factors for gallstone disease
  6. Opinion Paper
  7. Measurement uncertainty of test kit results – the ELISA example
  8. Genetics and Molecular Diagnostics
  9. Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters
  10. High-sensitive microarray substrates specifically designed to improve sensitivity for the identification of fetal paternally inherited sequences in maternal plasma
  11. A new CYP21A2 nonsense mutation causing severe 21-hydroxylase deficiency
  12. The haptoglobin phenotype is associated with the Epstein-Barr virus antibody titer
  13. General Clinical Chemistry and Laboratory Medicine
  14. Evaluation of analytical performance of the Pathfast® cardiac troponin I
  15. Diagnostic performance of the ARCHITECT C-Peptide immunoassay
  16. Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection
  17. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis
  18. Therapeutic drug monitoring and drugs of abuse testing on the cobas® 6000 analyzer series: analytical performance under routine-like conditions
  19. Is serum γ-glutamyltransferase an exposure marker of xenobiotics? Empirical evidence with polycylic aromatic hydrocarbon
  20. Reference Values and Biological Variations
  21. Gender difference and determinants of C-reactive protein level in Korean adults
  22. Cancer Diagnostics
  23. Quantitative telomerase activity in circulating human leukocytes: utility of real-time telomeric repeats amplification protocol (RQ-TRAP) in a clinical/epidemiological setting
  24. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers
  25. Letters to the Editor
  26. Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis
  27. Review of the prevalence of macroprolactinaemia in a South African hospital
  28. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program
  29. Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions
  30. Doubt on prevention of false-positive results of cardiac troponin I by recentrifugation
  31. Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson's disease
Heruntergeladen am 7.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2009.182/pdf
Button zum nach oben scrollen